Lestaurtinib is a first-generation, type I tyrosine kinase inhibitor with activity against a range of receptor tyrosine kinases including FLT3 (reviewed in Larrosa-Garcia and Baer, 2017; Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to lestaurtinib-mediated inhibition.
Larrosa-Garcia, M, Baer, MR
Daver, N, Schlenk, RF, Russell, NH, Levis, MJ
Staudt, D, Murray, HC, McLachlan, T, Alvaro, F, Enjeti, AK, Verrills, NM, Dun, MD
© 2021 Reactome